See more : AO World plc (AO.L) Income Statement Analysis – Financial Results
Complete financial analysis of Organovo Holdings, Inc. (ONVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Organovo Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Zhuhai Zhongfu Enterprise Co.,Ltd (000659.SZ) Income Statement Analysis – Financial Results
- Bintulu Port Holdings Berhad (5032.KL) Income Statement Analysis – Financial Results
- REAL ECO-ENERGY LIMITED (REALECO.BO) Income Statement Analysis – Financial Results
- Euroespes, S.A. (EEP.MC) Income Statement Analysis – Financial Results
- NAFCO Co., Ltd. (2790.T) Income Statement Analysis – Financial Results
Organovo Holdings, Inc. (ONVO)
About Organovo Holdings, Inc.
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109.00K | 370.00K | 1.50M | 0.00 | 2.20M | 3.09M | 4.60M | 4.23M | 1.48M | 571.00K | 379.00K | 1.20M | 0.00 |
| Cost of Revenue | 0.00 | 293.00K | 142.00K | 41.00K | 328.00K | 482.00K | 1.03M | 956.00K | 18.01M | 12.92M | 7.97M | 4.34M | 0.00 |
| Gross Profit | 109.00K | 77.00K | 1.36M | -41.00K | 1.87M | 2.61M | 3.57M | 3.27M | -16.53M | -12.35M | -7.60M | -3.14M | 0.00 |
| Gross Profit Ratio | 100.00% | 20.81% | 90.53% | 0.00% | 85.06% | 84.41% | 77.62% | 77.40% | -1,114.30% | -2,162.87% | -2,003.96% | -262.32% | 0.00% |
| Research & Development | 5.50M | 8.89M | 3.32M | 1.10M | 5.28M | 14.75M | 17.96M | 19.55M | 18.01M | 12.92M | 7.97M | 3.44M | 0.00 |
| General & Administrative | 9.64M | 9.09M | 9.63M | 15.71M | 17.15M | 0.00 | 0.00 | 22.30M | 22.12M | 17.95M | 0.00 | 0.00 | 120.09K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.64M | 9.09M | 9.63M | 15.71M | 17.15M | 15.13M | 20.89M | 22.30M | 22.12M | 17.95M | 13.05M | 7.08M | 120.09K |
| Other Expenses | 0.00 | 128.00K | 28.00K | 15.00K | 909.00K | 0.00 | -12.00K | 0.00 | 0.00 | 0.00 | 0.00 | -9.00K | 120.09K |
| Operating Expenses | 15.20M | 18.10M | 12.98M | 16.83M | 23.34M | 29.88M | 38.84M | 41.85M | 40.13M | 30.87M | 21.03M | 10.52M | 120.09K |
| Cost & Expenses | 15.20M | 18.10M | 12.98M | 16.83M | 23.67M | 30.37M | 39.87M | 42.81M | 40.13M | 30.87M | 21.03M | 10.52M | 120.09K |
| Interest Income | 405.00K | 454.00K | 8.00K | 15.00K | 594.00K | 705.00K | 478.00K | 198.00K | 88.00K | 32.00K | 18.00K | 5.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 8.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 13.00K | 1.09M | 0.00 |
| Depreciation & Amortization | 280.00K | 293.00K | 142.00K | 41.00K | 1.14M | 983.00K | 1.27M | 1.15M | 815.00K | 472.00K | 387.00K | 195.00K | 2.28K |
| EBITDA | -14.81M | -17.44M | -11.34M | -16.78M | -20.33M | -26.29M | -34.00M | -37.43M | -37.83M | -29.61M | -25.45M | -26.00M | -1.12M |
| EBITDA Ratio | -13,583.49% | -4,718.38% | -755.80% | 0.00% | -954.96% | -848.63% | -738.82% | -880.09% | -2,544.84% | -5,217.69% | -5,341.42% | -940.52% | 0.00% |
| Operating Income | -15.09M | -17.73M | -11.48M | -16.83M | -21.48M | -27.27M | -35.27M | -38.58M | -38.64M | -30.30M | -20.65M | -9.32M | -147.82K |
| Operating Income Ratio | -13,840.37% | -4,792.16% | -765.27% | 0.00% | -977.91% | -882.37% | -766.26% | -911.94% | -2,605.73% | -5,305.95% | -5,448.28% | -778.53% | 0.00% |
| Total Other Income/Expenses | 417.00K | 474.00K | 33.00K | 2.00K | 2.77M | 642.00K | 470.00K | 151.00K | 71.00K | 215.00K | -5.20M | -34.23M | -1.19M |
| Income Before Tax | -14.67M | -17.26M | -11.45M | -16.82M | -18.71M | -26.63M | -34.80M | -38.42M | -38.57M | -30.08M | -25.85M | -43.55M | -147.82K |
| Income Before Tax Ratio | -13,457.80% | -4,664.05% | -763.07% | 0.00% | -851.91% | -861.60% | -756.05% | -908.37% | -2,600.94% | -5,268.30% | -6,820.05% | -3,638.51% | 0.00% |
| Income Tax Expense | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K | 3.00K | 2.00K | 23.00K | 3.00K | -215.00K | 5.20M | 34.23M | 27.72K |
| Net Income | -14.67M | -17.26M | -11.45M | -16.83M | -18.71M | -26.64M | -34.80M | -38.45M | -38.58M | -30.08M | -25.85M | -43.55M | -147.82K |
| Net Income Ratio | -13,459.63% | -4,664.59% | -763.20% | 0.00% | -852.00% | -861.70% | -756.09% | -908.91% | -2,601.15% | -5,268.30% | -6,820.05% | -3,638.51% | 0.00% |
| EPS | -1.60 | -1.98 | -1.32 | -2.44 | -2.89 | -4.62 | -6.49 | -7.87 | -8.57 | -7.55 | -7.07 | -13.03 | -0.04 |
| EPS Diluted | -1.60 | -1.98 | -1.32 | -2.44 | -2.89 | -4.62 | -6.49 | -7.87 | -8.35 | -7.55 | -7.07 | -20.19 | -0.04 |
| Weighted Avg Shares Out | 9.14M | 8.71M | 8.70M | 6.90M | 6.48M | 5.77M | 5.36M | 4.89M | 4.50M | 3.98M | 3.66M | 3.34M | 3.60M |
| Weighted Avg Shares Out (Dil) | 9.14M | 8.71M | 8.70M | 6.90M | 6.48M | 5.77M | 5.36M | 4.89M | 4.62M | 3.98M | 3.66M | 2.16M | 3.60M |
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its oral presentation of its lead...
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its lead clinical stage drug, FXR314...
Nio stock poised for 42% gain on ONVO sales momentum
Nio Inc (NYSE: NIO) opened more than 10% up on Thursday after a JPMorgan analyst issued a super bullish note in its favour. Nick Lai now sees upside in the EV stock to $8.0.
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on...
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
Poster presented at DDW2024 demonstrating the potential of the Company's clinical-stage compound, FXR314, in combination with tofacitinib for treating IBD.
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Organovo will be presenting data on the Company's lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today...
Organovo's fatty liver disease drug meets main goal in mid-stage study
Organovo Holdings said on Monday its experimental drug to treat a type of fatty liver disease met the main goal in a mid-stage study, sending its shares up nearly 27% in premarket trade.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Conte
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis, based on demonstration of clinical promise in three-dimensional (3D) human...
Source: https://incomestatements.info
Category: Stock Reports